A comprehensive safety evaluation will enable healthcare professionals to develop more effective personalized treatment plans, optimize the use of SGLT-2 inhibitors, and improve the overall prognosis for non-diabetic CKD patients (22). The gene discussed is SLC5A2; the disease is chronic kidney disease.